PharmaShots

JUNE 29, 2023

The company focuses on developing organic spirulina and microalgae products under its Nutraceutical division as a type of dietary supplement. The company focuses on developing organic spirulina and microalgae products under its Nutraceutical division as a type of dietary supplement. Revenue: $277.2M Revenue: $277.2M

Immunization 40

Immunization 40

Pharma Marketing Network

DECEMBER 17, 2021

The pharma industry has been slower to embrace digital technologies than other less-regulated sectors but the COVID-19 pandemic has greatly changed this long-standing mindset. In 2020 and 2021, we saw pharma forced to become more flexible and open-minded than ever before. HCP Engagement and Pharma Salesforces.

Customer Service 105

Customer Service Vaccines Communication 105

pharmaphorum

NOVEMBER 23, 2020

German digital health company smartpatient is adding a new section of its MyTherapy app providing information on wet age-related macular degeneration (AMD), a leading cause of blindness. Wet AMD affects more than 20 million people worldwide, and is the top cause of blindness in people aged over 65. billion from the drug.

Communication 98

Communication 98

pharmaphorum

MAY 5, 2021

Pfizer expects revenues from its BioNTech-partnered COVID-19 vaccine to reach an eye-watering $26 billion this year, catapulting it to the top of the world’s biggest-selling medicines. . billion – so revenues could come in even higher if that surplus is snapped up. The vaccine made $3.5 1.351 strain. 1.351 strain.

Vaccines 105

Vaccines Pharmaceutical Companies Pharmaceutical Companies FDA 105

pharmaphorum

JANUARY 29, 2023

The rapid pace of growth and change means healthcare companies need our services, such as access to finance and capital markets, or strategic mergers and acquisitions advice. On top of that, relentless innovation is improving treatments and medical devices, bringing new opportunities to fight illness and disability.

Nursing Homes 98

Nursing Homes Hospitals Vaccines 98

PharmaShots

FEBRUARY 21, 2023

Shots: Integrating scintigraphy with therapeutics, radiopharmaceutical companies have emerged profoundly in the past few decades. With the growing influence of radiopharmaceutical companies in oncology, the companies hold a firm grasp on the market. threshold by 2026. threshold by 2026.

FDA 56

FDA Dosage Pharmaceutical Companies Pharmaceutical Companies 56

PharmaShots

JANUARY 31, 2023

Shots: Immutable capital demands and high-spending drug development plans are the most common drivers in encouraging fully-fledged private healthcare companies to go public. The company bagged its $6.3M LP-310, another lead asset of the company received FDA Type-B Pre-IND guidance recently for Oral Lichen Planus. of Shares: 1.5M

Vaccines 40

Vaccines Immunization FDA 40

PharmaShots

APRIL 25, 2023

In 2022, the global market size of RNAi drug delivery was valued at $69.2B. Stock Exchange: NASDAQ Silence Therapeutics, an emerging biotech company in the siRNA therapeutic industry, aims to design and develop siRNAs to meet the growing needs of patients with insufficient therapy options. R&D Expenditure: $84.4M

HIV Treatment and Prevention Agents 40

HIV Treatment and Prevention Agents Packaging Immunization Vaccines 40

PharmaShots

MARCH 29, 2023

Shots: Drug patent expiry is when a patent granted to a pharmaceutical company for a particular drug expires, allowing other companies to produce and sell generic versions Like every other utility patent, pharmaceuticals also get market exclusivity of 20 years. Currently, the drug is not accessible in generic form.

FDA 49

FDA Chemotherapy Immunization Dosage 49

PharmaShots

MAY 24, 2023

Revenue Analysis1 Trikafta/Kaftrio is developed and commercialized by Vertex Pharmaceuticals. In 2022, Vertex Pharma’s net product revenue spiked by 18%, vs. 2021, mainly due to influx of Trikafta in multiple countries internationally and the growing performance of Trikafta in the U.S.

Insurance Coverage 56

Insurance Coverage FDA Hospitals Dosage 56

PharmaShots

APRIL 12, 2023

Shots: Biopharma companies have kept themselves afloat in the ocean of uncertainties by overcoming the hurdles of unmet demands, procurement, and maintaining a constant supply chain. The company's mRNA platform comprises advances across three components, i.e., mRNA, delivery, and the manufacturing process.

Vaccines 64

Vaccines FDA Pharmaceutical Companies Pharmaceutical Companies 64

PharmaShots

APRIL 13, 2023

Such as inclination towards the Pharma 4.0 Such as inclination towards the Pharma 4.0 To be relevant and productive in the era of perpetual innovation, biopharma companies are embracing every necessary aspect of the modern world. model, the pharma 4.0 On the other hand, the company’s revenue recorded a $2.9M

Vaccines 40

Vaccines Pharmaceutical Companies Pharmaceutical Companies Labelling 40

pharmaphorum

MAY 31, 2022

In February, the company reacquired full rights to the shot from Astellas, which paid $10 million upfront to license the vaccine in 2017, clearing the way for GSK’s acquisition. billion in the previous year, but revenues bounced back in the first quarter of 2022, rising 59% to $1.57 billion in sales last year.

Vaccines 52

Vaccines Immunization FDA 52

PharmaShots

APRIL 26, 2023

PharmaShots presents an informative take on the key features of Dupixent with a detailed analysis of its revenue, clinical trials, alternatives, and approvals. Both companies collaborated on the global development and commercialization of Dupixent, Kevzara, and itepekimab (the "Antibody Collaboration"). mL, 100 mg/0.67

FDA 56

FDA Dosage 56

ISPE

JULY 6, 2023

Considerable uncertainty exists, however, among manufacturers regarding the costs and benefits of CM technology, including several risks that, so far, are holding companies back from making the leap to CM. Leveraging SRM Concepts for CM SRM provides a formalized structure about the way in which a company manages its various risks.

Insurance 52

Insurance Documentation Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JANUARY 6, 2022

In the second part of our examination of issues that will shape the course of 2022, we’ll update the ongoing impacts of the pandemic, which have, as they did in 2021, a pervasive effect on both pharma and healthcare issues, with themes we highlighted at the beginning of 2021 continuing their impact. RNA Therapeutics come to the fore.

Vaccines 110

Vaccines Pharmaceutical Companies Pharmaceutical Companies 110

ISPE

MARCH 6, 2023

[link] A recent study published by My Green Lab 2 presented data from 74 biotechnology and pharmaceutical companies tracking the change in scope 1, 2, and 3 carbon intensity (measured in tons of CO2 emitted vs. the company’s revenue in USD) since 2015. But most companies do not. Revised November 2022.

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies Compounding 52

Pharmaceutical Technology

APRIL 24, 2023

With new drugs on the market, companies are now looking for ways to manufacture recently approved biologics, and countries are racing to claim their corner – or maintain their decades-old market share. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures.

Vaccines 52

Vaccines Compounding Pharmaceutical Companies Pharmaceutical Companies 52